

ASX RELEASE

30<sup>th</sup> July 2020

### Entitlement Offer Completed

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has had strong support for the Retail Entitlement Offer component of its fully underwritten, accelerated, non-renounceable entitlement offer (**Entitlement Offer**). This completes the Entitlement Offer which was announced on 1<sup>st</sup> July 2020 and has raised a total of approximately \$4.0 million at \$0.10 per new share (**New Shares**).

Eligible Retail Shareholders were entitled to apply for up to 3 New Shares for every 5 shares they held on Friday 3<sup>rd</sup> July 2020 (**Record Date**) and were able to subscribe for New Shares over and above their Entitlement under a Shortfall Facility. Amplia received valid applications from eligible retail shareholders for 18.3 million New Shares, representing approximately 92% of the New Shares offered under the \$2.0 million Retail Entitlement Offer. The shortfall of 1.7 million shares will be placed by the Underwriter.

A total of 39.9 million new fully paid ordinary shares were issued under the Entitlement Offer. The Institutional Entitlement Offer, which raised \$2.0 million and was announced on 3<sup>rd</sup> July 2020, was strongly supported by the Company’s largest shareholder, Platinum Investment Management Ltd. and a new substantial shareholder, Blueflag Holdings Pty Ltd.

The proceeds from the Entitlement Offer will be used to fund a Phase 1 clinical trial of the Company’s FAK inhibitor drug AMP945, additional non-clinical studies and provide working capital for the Company.

Commenting on the results of the Entitlement Offer, Amplia’s Chief Executive Officer Dr John Lambert said “We are very encouraged to see such strong support and commitment for Amplia from both our institutional and retail shareholders. We see the transition to becoming a clinical stage company as an important and exciting milestone and we are delighted with the support we have seen from our shareholders as we make that transition.”

Taylor Collison acted as Underwriter and Lead Manager to the Offer.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

#### For Further Information

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).